AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site
Developers ranging from academic institutions to biotechnology companies select AGC Biologics for its proven commercial track record
Showcases momentum for Japan’s cell and gene therapy ecosystem following proactive government initiatives
YOKOHAMA, Japan, Nov. 16, 2026 (GLOBE NEWSWIRE) -- While there is growing interest and momentum for cell and gene therapy development in Japan, there are a limited number of CDMOs with the institutional knowledge, manufacturing prowess, talent development, and international network. To advance their projects in a fast-paced, resource-constrained environment, three biopharma developers including the Institute of Science Tokyo have selected AGC Biologics to provide cell therapy services from its new Yokohama location.
AGC established its cell therapy services in Yokohama in July 2025, bringing together two strong legacies: thirty years of expertise and the track record of the AGC Biologics Milan site, and AGC Group’s century-plus manufacturing excellence in Japan. Combined, those legacies position AGC to meet the burgeoning needs of the cell and gene therapy industry.

As part of these new projects, the AGC Biologics Yokohama site will provide services such as process transfer and manufacturing services for pre-clinical and clinical trials. Core technologies available for developers with diverse needs include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, exosomes, and CAR-T cell therapies.
Supporting Clinical Translation of Virus-Specific T Cell Therapy Research
Among the projects the Yokohama site will support is a research program led by the Institute of Science Tokyo aimed at advancing third-party virus-specific T cell therapy for treatment-resistant adenovirus infections following hematopoietic cell transplantation toward clinical application.
“Viral infections following hematopoietic cell transplantation represent a major clinical challenge in patients with compromised immune function and can lead to severe, potentially life-threatening complications," said Takahiro Kamiya, M.D., Ph.D., Junior Associate Professor at the Institute of Science Tokyo Graduate School of Medical and Dental Sciences. “With support from the Japanese Agency for Medical Research and Development under its Research Program for Intractable Diseases, we are advancing the research and development of virus-specific T-cell therapy toward clinical implementation for refractory adenovirus infections following hematopoietic cell transplantation.”
At the Yokohama site, AGC Biologics supports this program through process development and analytical method development activities intended to facilitate future clinical and manufacturing implementation.
Coordination with the AGC Biologics Milan Cell and Gene Center of Excellence
One of the new projects involves the transfer of a customer program from the Milan site to the Yokohama site, where AGC will conduct future development and manufacturing activities. Through coordination across its global network, AGC Biologics provides flexible development and manufacturing support tailored to customers' evolving needs and business environments.
“By combining technologies developed across our global network with AGC's unique materials expertise, we provide globally aligned development support services to customers worldwide,” said Tadashi Murano, President of AGC Life Science Company. “Going forward, we will continue to provide integrated support from early-stage development through commercialization, helping accelerate our customers' research and development activities.”
“AGC Biologics has accumulated extensive experience in the development and manufacturing of cell therapy products through its global operations,” said Takahiro. “As we prepare for this collaboration, we have also been impressed by the strength of its research and development capabilities, its robust infrastructure, and the dedication and enthusiasm of its team.”
Development and manufacturing provided by the AGC Biologics Cell and Gene Technologies Division has led to 18 commercial approvals for its customers and their products.
Improved landscape for cell and gene therapy development in Japan
As outlined in a recent analysis by Dark Horse Consulting and AGC Biologics, proactive government action and regulatory changes have brought a new wave of early-stage development and attention to cell and gene therapy development in Japan.
“As Western biopharmaceuticals and investors increasingly turn their attention eastward, much of the spotlight has centered on China, driven by its scale, clinical speed and cost advantages,” according to H. Deborah Chen and Kang Liu, the authors of the new report, From Laboratory to Launchpad: Japan's Cell and Gene Therapy Ecosystem Hits Its Stride. “Yet, Japan with its deep scientific expertise, expanding manufacturing infrastructure, and strong global accessibility represents both a growing market and a potential hub for CGT innovation across Asia that should not be overlooked.”
The full report outlines why Japan presents a compelling opportunity for global CGT developers, as well as some key considerations for developers aiming to build a presence or conduct trials in Japan.
Frequently Asked Questions (FAQs):
Will the Yokohama cell therapy services only be approved by the PMDA, or will it pursue products for additional international regulatory approvals?
The Yokohama cell therapy services suite will not be limited to any one jurisdiction and will pursue regulatory approvals as desired by the customers and the markets they wish to serve, including the PMDA, FDA, EMA, and others.
The AGC Biologics unified global quality system brings a consistent track record of regulatory success and manufacturing excellence to its partnerships and has worked with regulatory bodies around the world and on four different continents. AGC Biologics has passed more than 100 regulatory inspections across agencies including the FDA, EMA, and PMDA.
What specifically is the SAKIGAKE designation and what is the status of it?
The SAKIGAKE designation system was initiated by Japan’s Ministry of Health, Labor and Welfare in 2015 to further accelerate regulatory approvals for innovative therapies. Similar to the U.S. FDA’s Breakthrough Therapy designation and the EU EMA’s Priority Medicines program, the SAKIGAKE regulatory initiative works to expedite access to treatments for serious or life-threatening conditions.
SAKIGAKE status is granted to candidates demonstrating novel mechanisms of action with promising efficacy or safety data, and those products have a review period closer to six months and prioritized consultation with the PMDA.
As of June 2026, four of the 25 regenerative medicine products receiving approval in Japan had SAKIGAKE designation. Three of the four were from Japanese drug developers and one was a global sponsor.
In late 2025 and early 2026 alone, four new SAKIGAKE designations were awarded to sponsors outside of Japan.
How does Japan encourage orphan drug development?
Japan’s Ministry of Health, Labor and Welfare has an orphan designation for products targeting conditions with fewer than 50,000 patients in Japan that have a high unmet medical need and lack effective existing treatments.
With this designation, sponsors have:
- Priority review timelines (~ 9 months)
- 10-year re-examination period
- Flexibility for global programs (Does not require a Japan-first or Japan-simultaneous submission)
More details are accessible through the PMDA’s Overview of Orphan Drug Designation.
About Institute of Science Tokyo
Institute of Science Tokyo (Science Tokyo) was established on October 1, 2024, following the merger between Tokyo Medical and Dental University (TMDU) and Tokyo Institute of Technology (Tokyo Tech), with the mission of “Advancing science and human wellbeing to create value for and with society.”
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering friendly and expert services as we work side-by-side with our clients and partners. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/44424b25-cd4c-4c22-9427-afbabaa3a55d
https://www.globenewswire.com/NewsRoom/AttachmentNg/5016e6ef-237d-479e-bf29-bde4c1b9ca7b
Institute of Science Tokyo media contact: media@adm.isct.ac.jp
AGC Inc. corporate contact: info-pr@agc.com
AGC Biologics media contact: kati.sills@agc.com
- Bitget TraderPro 第 3 季采取“从模拟交易到真实交易”赛制,每位用户可获得高达 10,000 美元的资金支持
- 《跟着课本去旅行》:新疆研学之旅圆满落幕,文旅融合开启新篇章
- AQUA爱克泳池温泉设备:以创新与卓越品质,赋能龙口温泉水疗项目
- 临商银行北城支行助力困难大学生圆梦大学
- Unlocking Capital: Over 20k traders unlocked their trading potential with Axi Select
- 加拿大的 La Tablée des Chefs 斩获 F1® Allwyn 全球社区奖,并获 10 万欧元捐款用于应对粮食供应危机
- 《城中之城》CCTV1、爱奇艺同步热播中,夏梦饰职场小白获好评
- LambdaTest Releases Accessibility DevTools Chrome Extension to Enhance Web Inclusivity
- AI赋能业财融合,企业还能这么玩?云简十周年现场揭秘!
- Lenovo在“2024年Lenovo创新世界大会”上发布人工智能驱动的创新产品
- 24小时完成新老交替,药易购这波操作够快
- 借力抖音买单生态赋能实体经营 ,云芯科创助力本地商家驶入数字化增长快车道
- 六安华科:深耕高效节能电机,以技术创新竞逐绿色智造新赛道
- 共筑纺织产业数字化新生态,抢占万亿级市场先机
- 你可以高度灵活定制的设备管理软件,居然永久免费
- 聆听城事共话未来 城市探访纪实节目《共同说》12月1日开播
- 佰年脉天然苏打水行业新星闪耀医联体大会,以其独特健康价值引领行业潮流
- 案件进度一目了然、权责分明:Alpha系统引领律所数字化管理新范式
- Iveco Group Calls the Extraordinary General Meeting for the Defence Business transaction
- 众恒集团发布“科技+金融”双引擎战略 明确聚焦前沿科技与责任发展路径
- Triple win for CNH brands at the 2026 Red Dot Design Awards
- 一城双展丨PhotonPay光子易亮相GTC2024&第七届全球跨境电商节,斩获两项殊荣
- Honda携海陆空全领域产品亮相北京车展
- 连锁门店遍地开花,浆小白为什么这么火?
- AI应用收入11.3亿元、人效提升85.6%:从Palantir到迈富时:企业AI为什么开始转向“部署效率”?
- 新一年,非遗营销怎样才能叫好又叫座?
- 铸铝门十大品牌领跑者!索菲赫凭高端品质征服豪宅圈
- 福田CBD写字楼物业找哪家?三和国际华富物业提供专业方案
- MicroVention更名为Terumo Neuro以反映业务重点扩展和战略增长
- 亿都加速布局AI算力赛道 旗下算丰信息TaaS业务正式进驻香港数码港





